Literature DB >> 15662519

[Positron emission tomography in neuroscience. An integrative part of clinical diagnostic methods and experimental research].

B Schaller1.   

Abstract

The role of molecular neuroimaging techniques is increasing in the understanding of pathophysiological mechanism of diseases. To date, positron emission tomography is the most powerful tool for the non-invasive study of biochemical and molecular processes in humans and animals in vivo. With the development in radiochemistry and tracer technology, a variety of endogenously expressed and exogenously introduced genes can be analyzed by PET. This opens up the exciting and rapidly field of molecular imaging, aiming at the non-invasive localisation of a biological process of interest in normal and diseased cells in animal models and humans in vivo. Besides its usefulness for basic research positron emission tomography has been proven to be superior to conventional diagnostic methods in several clinical indications. This is illustrated by detection of biological or anatomic changes that cannot be demonstrated by computed tomography or magnetic resonance imaging, as well as even before symptoms are expressed. The present review summarizes the clinical use of positron emission tomography in neuroscience that has helped elucidate the pathophysiology of a number of diseases and has suggested strategies in the treatment of these patients. Special reference is given to the neurovascular, neurodegenerative and neurooncological disease.

Entities:  

Mesh:

Year:  2005        PMID: 15662519     DOI: 10.1007/s00117-004-1158-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  79 in total

1.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

2.  Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease.

Authors:  W D Heiss; J Kessler; I Slansky; R Mielke; B Szelies; K Herholz
Journal:  Ann N Y Acad Sci       Date:  1993-09-24       Impact factor: 5.691

3.  Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation.

Authors:  W D Heiss; J Kessler; R Mielke; B Szelies; K Herholz
Journal:  Dementia       Date:  1994 Mar-Apr

4.  Preoperative activation and intraoperative stimulation of language-related areas in patients with glioma.

Authors:  K Herholz; H J Reulen; H M von Stockhausen; A Thiel; J Ilmberger; J Kessler; W Eisner; T A Yousry; W D Heiss
Journal:  Neurosurgery       Date:  1997-12       Impact factor: 4.654

5.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease.

Authors:  M Iyo; H Namba; K Fukushi; H Shinotoh; S Nagatsuka; T Suhara; Y Sudo; K Suzuki; T Irie
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

Review 6.  The current status of PET scanning with respect to schizophrenia.

Authors:  G Sedvall
Journal:  Neuropsychopharmacology       Date:  1992-08       Impact factor: 7.853

7.  [F-18 fluorodeoxyglucose positron emission tomography in neurology].

Authors:  F Fazekas; F Payer
Journal:  Wien Med Wochenschr       Date:  2002

8.  Repeated fluorodeoxyglucose positron emission tomography of the brain in infants with suspected hypoxic-ischaemic brain injury.

Authors:  H Suhonen-Polvi; P Kero; H Korvenranta; U Ruotsalainen; M Haaparanta; J Bergman; O Simell; U Wegelius
Journal:  Eur J Nucl Med       Date:  1993-09

9.  Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-Methionine.

Authors:  P Bustany; M Chatel; J M Derlon; F Darcel; P Sgouropoulos; F Soussaline; A Syrota
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

Review 10.  Pathogenesis and treatment of neuroleptic malignant syndrome.

Authors:  M Ebadi; R F Pfeiffer; L C Murrin
Journal:  Gen Pharmacol       Date:  1990
View more
  4 in total

1.  Molecular medicine successes in neuroscience.

Authors:  Bernhard Schaller; Jan F Cornelius; Nora Sandu
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

Review 2.  Current molecular imaging of spinal tumors in clinical practice.

Authors:  Nora Sandu; Gabriele Pöpperl; Marie-Elisabeth Toubert; Toma Spiriev; Belachew Arasho; Mikael Orabi; Bernhard Schaller
Journal:  Mol Med       Date:  2011-01-03       Impact factor: 6.354

3.  Molecular imaging of stem cell therapy in brain tumors: a step towards personalized medicine.

Authors:  Nora Sandu; Bernhard Schaller
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

4.  Commentary.

Authors:  Nora Sandu; Bernhard Schaller
Journal:  J Neurosci Rural Pract       Date:  2014-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.